SEC	Form	4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

		4		017		0.01	-001											
							V	Nash	ington, D.C.	. 205	549					OME	APPRO	VAL
Section obligat	this box if no lo n 16. Form 4 or ions may contir tion 1(b).	nger subject to Form 5 nue. <i>See</i>	STATEMENT OF CHANGES IN BENEFICIAL OWN Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940									SHIP	Estim		er: verage burde sponse:	3235-0287 n 0.5		
transac contrac the pur securit to satis conditio	chase or sale of	pursuant to a rwritten plan for of equity r that is intended ve defense																
1. Name and Address of Reporting Person* KASINGER JAMES R.					2. Issuer Name and Ticker or Trading Symbol <u>CRISPR Therapeutics AG</u> [CRSP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
	SPR THER	APEUTICS	(Middle)			3. Date of Earliest Transaction (Month/Day/Year)						(give title Other (spe			specify			
(Street) BOSTO	ST FIRST S		02127		4.1	If Ame	ndment, I	Date	of Original F	Filed	1 (Month/Da	iy/Year)		Form f	iled by On	e Repo	g (Check Ap orting Perso n One Repo	n
(City)	(S	tate)	(Zip) Person															
		Tab	ole I - Nor	n-Deriv	ativ	e Se	curities	s Ac	quired,	Dis	posed o	f, or Be	neficia	lly Owned	ł			
1. Title of Security (Instr. 3) 2. Trans Date (Month/I				action 2A. Deemed Execution Date, if any (Month/Day/Yea			Code (Instr. 5)			Benefici Owned F	es Form ially (D) o Following (I) (II		n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) o (D)	r Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)	
		-	Table II - I						uired, Di s, option					y Owned				
1. Title of Derivative Security (Instr. 3) 22. 3. Transaction Derivative Or Exercise Price of Derivative Security			3A. Deemed 4. Execution Date, if any (Month/Day/Year) 8)		Transa Code (ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirec Beneficia Ownershi (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amount or Number of Shares	1				
Stock Option (Right to Buy)	\$49	10/16/2024			Α		18,333		(1)		10/16/2034	Common Shares	18,333	\$ \$0.00	18,33	33	D	
Restricted Stock Units	(2)	10/16/2024			Α		30,000		(3)		(3)	Common Shares	30,000	\$0.00	30,00)0	D	

Explanation of Responses:

1. This option was granted on October 16, 2024 with respect to 18,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 16, 2024.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. This restricted stock unit award was granted on October 16, 2024 with respect to 30,000 Common Shares, with 100% of the shares vesting on October 16, 2027.

/s/ Elizabeth Ryland Waldinger, 10/18/2024 attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.